Neonatal lupus erythrematosus overview: Difference between revisions
Jump to navigation
Jump to search
Mahmoud Sakr (talk | contribs) No edit summary |
Mahmoud Sakr (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Neonatal lupus erythrematosus}} | {{Neonatal lupus erythrematosus}} | ||
{{CMG}}; {{AE {{MS}} | {{CMG}}; {{AE}} {{MS}} | ||
Neonatal lupus (NL) is an autoimmune disease of neonates that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus (SLE) and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.<ref name="pmid20012231">{{cite journal| author=Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J| title=Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. | journal=Clin Rev Allergy Immunol | year= 2011 | volume= 40 | issue= 1 | pages= 27-41 | pmid=20012231 | doi=10.1007/s12016-009-8190-6 | pmc=PMC3558034 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20012231 }} </ref><ref name="pmid19852749">{{cite journal| author=Buyon JP| title=Updates on lupus and pregnancy. | journal=Bull NYU Hosp Jt Dis | year= 2009 | volume= 67 | issue= 3 | pages= 271-5 | pmid=19852749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19852749}} </ref>. It is characterized by cutaneous, cardiac or rarely both clinical manifestations. | Neonatal lupus (NL) is an autoimmune disease of neonates that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus (SLE) and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.<ref name="pmid20012231">{{cite journal| author=Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J| title=Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. | journal=Clin Rev Allergy Immunol | year= 2011 | volume= 40 | issue= 1 | pages= 27-41 | pmid=20012231 | doi=10.1007/s12016-009-8190-6 | pmc=PMC3558034 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20012231 }} </ref><ref name="pmid19852749">{{cite journal| author=Buyon JP| title=Updates on lupus and pregnancy. | journal=Bull NYU Hosp Jt Dis | year= 2009 | volume= 67 | issue= 3 | pages= 271-5 | pmid=19852749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19852749}} </ref>. It is characterized by cutaneous, cardiac or rarely both clinical manifestations. | ||
Revision as of 19:55, 23 August 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]
Neonatal lupus (NL) is an autoimmune disease of neonates that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus (SLE) and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.[1][2]. It is characterized by cutaneous, cardiac or rarely both clinical manifestations.
References
- ↑ Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J (2011). "Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies". Clin Rev Allergy Immunol. 40 (1): 27–41. doi:10.1007/s12016-009-8190-6. PMC 3558034. PMID 20012231.
- ↑ Buyon JP (2009). "Updates on lupus and pregnancy". Bull NYU Hosp Jt Dis. 67 (3): 271–5. PMID 19852749.